Preclinical evaluation of a novel and orally active proteasome inhibitor as a therapy in relapsed/refractory multiple myeloma

被引:0
|
作者
Chauhan, D
Catley, L
Li, G
Hideshima, T
Richardson, P
Palladino, M
Anderson, KC
机构
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Nereus Pharmaceut, San Diego, CA USA
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
引用
收藏
页码:222S / 222S
页数:1
相关论文
共 50 条
  • [31] Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma
    Kumar, Shaji K.
    Bensinger, William I.
    Zimmerman, Todd M.
    Reeder, Craig B.
    Berenson, James R.
    Berg, Deborah
    Hui, Ai-Min
    Gupta, Neeraj
    Di Bacco, Alessandra
    Yu, Jiang
    Shou, Yaping
    Niesvizky, Ruben
    BLOOD, 2014, 124 (07) : 1047 - 1055
  • [32] VENETOCLAX AS TARGETED THERAPY FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA
    Kumar, S.
    Kaufman, J. L.
    Mikhael, J.
    Gasparetto, C.
    Vij, R.
    Pegourie, B.
    Benboubker, L.
    Facon, T.
    Moreau, P.
    Amiot, M.
    Alzate, S.
    Dunbar, M.
    Xu, T.
    Agarwal, S.
    Leverson, J.
    Ross, J.
    Maciag, P.
    Verdugo, M.
    Touzeau, C.
    HAEMATOLOGICA, 2017, 102 : 268 - 269
  • [33] Venetoclax salvage therapy in relapsed/refractory multiple myeloma
    Steinhardt, M.
    Truger, M.
    Bittrich, M.
    Zhou, X.
    Noderer, J.
    Riedhammer, C.
    Xiao, X.
    Gawlas, S.
    Philipp, W.
    Eisele, F.
    Haferlach, C.
    Mersi, J.
    Waldschmidt, J.
    Einsele, H.
    Rasche, L.
    Kortuem, K. M.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 58 - 58
  • [34] Venetoclax salvage therapy in relapsed/refractory multiple myeloma
    Steinhardt, Maximilian J.
    Truger, Marietta
    Bittrich, Max
    Zhou, Xiang
    Noderer, Julia
    Riedhammer, Christine
    Xiao, Xianghui
    Gawlas, Sophia
    Weis, Philipp
    Eisele, Florian
    Haferlach, Claudia
    Mersi, Julia
    Waldschmidt, Johannes
    Einsele, Hermann
    Rasche, Leo
    Kortuem, K. Martin
    HAEMATOLOGICA, 2024, 109 (03) : 979 - 981
  • [35] LENALIDOMIDE THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
    Okada, K.
    Okamoto, Y.
    Tsukamoto, T.
    Sugiura, H.
    Matsui, H.
    Ueda, T.
    Jo, T.
    Onishi, T.
    Kunitomi, A.
    Ueda, Y.
    ANNALS OF ONCOLOGY, 2013, 24
  • [36] The activity and safety of novel proteasome inhibitors strategies (single, doublet and triplet) for relapsed/refractory multiple myeloma
    Ma, Huanwen
    Su, Zheng
    Sun, Fengqiang
    Zhao, Ningning
    ACTA ONCOLOGICA, 2018, 57 (02) : 290 - 296
  • [37] NK cell therapy in relapsed refractory multiple myeloma
    Roshandel, Elham
    Ghaffari-Nazari, Haniyeh
    Mohammadian, Mozhdeh
    Salimi, Maryam
    Abroun, Saeid
    Mirfakhraie, Reza
    Hajifathali, Abbas
    CLINICAL IMMUNOLOGY, 2023, 246
  • [38] Bendamustine therapy for advanced relapsed/refractory multiple myeloma
    Shkury, Eden
    Geva, Mika
    Avigdor, Abraham
    Nevo, Lee
    Magen, Hila
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S189 - S189
  • [39] Venetoclax as Targeted Therapy for Relapsed/Refractory Multiple Myeloma
    Kumar, S.
    Kaufman, J. L.
    Mikhael, J.
    Gasparetto, C.
    Vij, R.
    Pegourie, B.
    Benboubker, L.
    Facon, T.
    Moreau, P.
    Amiot, M.
    Alzate, S.
    Dunbar, M.
    Xu, T.
    Agarwal, S.
    Leverson, J.
    Ross, J.
    Maciag, P.
    Verdugo, M.
    Touzeau, C.
    BRITISH JOURNAL OF HAEMATOLOGY, 2018, 181 : 100 - 101
  • [40] Venetoclax as Targeted Therapy for Relapsed/Refractory Multiple Myeloma
    Kumar, Shaji
    Kaufman, Jonathan L.
    Mikhael, Joseph
    Gasparetto, Cristina
    Vij, Ravi
    Pegourie, Brigitte
    Benboubker, Lofti
    Facon, Thierry
    Moreau, Philippe
    Amiot, Martine
    Alzate, Stefanie
    Dunbar, Martin
    Xu, Tu
    Agarwal, Suresh
    Leverson, Joel
    Ross, Jeremy
    Maciag, Paulo
    Verdugo, Maria
    Touzeau, Cyrille
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E27 - E27